TABLE 1.

Histologic and MMDx diagnoses and DSA in the TCMR1 vs TCMR2 biopsy groups in the 175 TCMR cohort

		Rejection archetype group
		All TCMR(N = 175)	TCMR1(N = 75)	TCMR2(N = 100)	P TCMR1 vs TCMR2
MMDx signout diagnoses
Rejection-related	AMR	5 (3%)	0	5 (5%)	0.07
	Possible AMR	0	0	0	1.00
	Mixed	57 (33%)	44 (59%)	13 (13%)	<0.0001
	TCMR	103 (59%)	31 (41%)	72 (72%)	<0.0001
	Possible TCMR	10 (6%)	0	10 (10%)	0.005
No rejection		0	0	0	1.00
Histology diagnoses
Rejection-related	AMR	8 (5%)	4 (5%)	4 (4%)	0.73
	Transplant glomerulopathy	3 (2%)	0	3 (3%)	0.26
	AMR suspected	2 (1%)	1 (1%)	1 (1%)	1.00
	Mixed	26 (15%)	18 (24%)	8 (8%)	0.003
	TCMR	73 (42%)	39 (52%)	34 (34%)	0.02
	TCMR/BK	3 (2%)	2 (3%)	1 (1%)	0.61
	Borderline rejection	12 (7%)	2 (3%)	10 (10%)	0.07
No rejection	BK nephropathy virus	24 (14%)	3 (4%)	21 (21%)	0.001
	No major abnormalities	4 (2%)	1 (1%)	3 (3%)	0.64
	Othersa	20 (11%)	5 (7%)	15 (15%)	0.09
DSA status
		N in all TCMR (% of N = 142 tested)	N in TCMR1(% of N = 59 tested)	N in TCMR2 (% of N = 83 tested)	P TCMR1 vs TCMR2
DSA positive		51 (36%)	24 (41%)	27 (33%)	0.32
DSA negative		91 (64%)	35 (59%)	56 (67%)
DSA missing/unknown		33	16	17

^aOthers includes diabetic nephropathy, glomerulonephritis, fibrosis and atrophy (IFTA), calcineurin inhibitor toxicity, C4d deposition without morphologic evidence for active rejection, donor origin vascular disease, pyelonephritis, systemic infection/diarrhea, and bacterial infection.

Chi-square was performed on the comparison of TCMR1 vs TCMR2 for each histologic diagnosis.

Bold values indicate significant difference between TCMR1 and TCMR2.

AMR, antibody-mediated rejection; DSA, donor-specific antibody; MMDx, Molecular Microscope Diagnostic System; TCMR, T cell–mediated rejection.